Delaney William E IV 4

What Happened

• William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences (ASMB), received a grant of 26,000 restricted stock units (RSUs) on March 29, 2026. The grant is reported at $0.00 per share (standard for RSU awards at grant; value will be realized if and when shares vest and are delivered).

Key Details

• Transaction date: 2026-03-29; Form 4 filed: 2026-03-31.
• Grant: 26,000 RSUs @ $0.00 per share (total reported $0 at grant).
• Vesting: RSUs vest in four equal annual installments on March 29 of 2027, 2028, 2029 and 2030 (per footnote F1).
• Contingency: The 26,000 RSUs represent 65% of his annual equity grant; the remaining 35% is contingent on stockholder approval to increase the number of shares available under the company’s 2018 Stock Incentive Plan (footnote F2).
• Prior holdings note: Filing references 2,909 shares acquired under the company ESPP on May 14, 2025 (footnote F3). Shares owned after this specific award are not specified in the provided excerpt.
• Filing timeliness: Form filed two days after the transaction date; no late-filing flag indicated.

Context

• RSUs are a form of compensation that convert into actual shares only upon vesting and delivery; this is not an open-market purchase (so it’s not a direct bullish buy signal). The contingent portion tied to shareholder approval means some of the total annual grant depends on a future vote. Grants like this are commonly used for retention and compensation.